Compugen’s Q1 Earnings Dip as Licensing Delays Loom

Forward-Looking Analysis

Analysts project Compugen’s Q1 2026 earnings will show modest revenue growth, with current estimates pointing to $67.5 million, up slightly from $67.33 million in Q4 2025. Net income is forecast to decline to $55 million, reflecting ongoing licensing negotiations for CGEN-301. EPS is expected at $0.59, down from $0.60 in the prior quarter. Jefferies downgraded Compugen to Market Outperformer with a $12.50 price target, citing regulatory uncertainty. Oppenheimer maintains an Outperform rating, but highlights delays in partnership progress as a near-term headwind. With no revenue diversification yet, all expectations are tied to CGEN-301 commercialization status, which remains uncertain.

Historical Performance Review

In Q4 2025, Compugen reported $67.33 million in revenue and $56.84 million in net income, yielding an EPS of $0.60. Gross profit stood at $63.80 million, reflecting strong margins despite low recurring revenue diversification.

Additional News

Compugen recently announced the initiation of Phase II trials for CGEN-301 in oncology, with initial results expected by Q3 2026. The company also expanded its R&D team by 15%, signaling a push toward pipeline diversification. Additionally, Compugen secured a $5 million grant from the Biomedical Innovation Fund to support its early-stage immunotherapy programs. CEO Dr. Karen Smith reaffirmed long-term goals in a recent investor call, emphasizing that CGEN-301 licensing remains a top priority despite near-term delays.

Summary & Outlook

Compugen enters Q1 2026 with a mixed financial profile: revenue and gross profit remain stable, but net income and EPS show slight declines due to licensing delays. While its robust R&D initiatives and early-stage grants highlight growth potential, the lack of partnership clarity poses a risk. A bullish stance is tempered by near-term uncertainty around CGEN-301 commercialization. Investors should watch for updates on licensing progress and Phase II trial data, which could serve as key catalysts for the stock in the second half of 2026.